Observational study on chronic Hepatitis B infection in Jiangsu
Official title: "Real-life" Cohort Study on Patients With Chronic Hepatitis B Virus Infection in Jiangsu
Run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · NCT03097952 · Data updated 2026-11-12
This study is collecting information from people with chronic Hepatitis B in Jiangsu, China, to see what factors might affect their health outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Academic / other |
| Locations | 6 sites (Changzhou, Jiangsu and 5 other locations) |
| Status | Recruiting |
| Started | January 2008 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | March 31, 2017 |
| Trial ID | NCT03097952 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals who have been diagnosed with chronic HBV infection, defined as being HBsAg positive for at least six months.
✕Probably not a fit
Patients with co-infections such as HIV, HCV, or HDV, as well as those with a history of liver transplantation or hepatocellular carcinoma, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study aims to gather data from non-selected patients with chronic Hepatitis B virus (HBV) infection in Jiangsu, China. The study will create a comprehensive database that includes epidemiological, clinical, biological, virological, immunologic, and therapeutic parameters. By analyzing these factors, the researchers hope to identify predictors of outcomes in patients suffering from chronic HBV infection, which remains a significant health concern worldwide.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of chronic HBV infection, potentially reducing the risk of severe outcomes such as cirrhosis and liver cancer.
How similar studies have gone: While there have been various studies on chronic HBV infection, this particular observational approach focusing on a non-selected cohort in Jiangsu is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with chronic HBV infection (defined as HBsAg positive for at least 6 months) Exclusion Criteria: * Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) and/or hepatitis D virus (HDV) * History of liver transplantation * History of hepatocellular carcinoma (HCC)
Where it's running
-
The Third Hospital of Changzhou
Changzhou, Jiangsu, China Recruiting -
Huai'an No.4 People's Hospital
Huai'an, Jiangsu, China Recruiting -
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China Recruiting -
Nanjing Jiangbei People's Hospital
Nanjing, Jiangsu, China Recruiting -
Suqian People's Hospital
Suqian, Jiangsu, China Recruiting -
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Chao Wu, M.D., Ph.D
- Email: dr.wu@nju.edu.cn
- Phone: 86-25-83105890
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AHB-137 for chronic hepatitis B in adults on nucleotide analogue therapy
AHB-137 is being tested to see if it is safe and effective for adults with chronic hepatitis B who are currently on nucleos(t)ide analogue therapy.
-
Oral and gum health and saliva markers in people with hepatitis B and D
This project will test whether gum inflammation and specific saliva and gum-fluid markers differ in adults with hepatitis B and D—both those taking bulevirtide and those not—compared with healthy adults.
-
Entecavir Resistance Mutations in chronic hepatitis B patients in Turkey
This study tests whether entecavir resistance mutations can be detected in adults with chronic hepatitis B, and whether prior lamivudine exposure increases the chance of those mutations appearing.
-
AHB-137 for HBeAg-negative chronic hepatitis B in the Asia–Pacific
This trial tests whether AHB-137 injections can improve outcomes for adults in the Asia–Pacific with HBeAg-negative chronic hepatitis B who are already on nucleos(t)ide therapy.
-
Sequential PEG-IFN for Hepatitis B After RNA-targeted Therapy
This study tests whether starting or delaying a 24-week course of pegylated interferon helps people with chronic hepatitis B who previously used ASO/siRNA therapies.
-
Evaluating a new gene therapy for chronic hepatitis B
This study is testing a new gene therapy for adults with chronic hepatitis B to see if it is safe and effective in fighting the virus.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.